STAAR disputes Broadwood’s claims about acquisition offers

LAKE FOREST, Calif. - STAAR Surgical Company (NASDAQ:STAA), currently valued at $1.2 billion, has issued a statement challenging claims made by Broadwood Partners regarding potential acquisition interest in the company, calling them "misleading" and a distortion of the truth. According to InvestingPro data, the company’s stock has seen a significant 60% price return over the past six months, highlighting the heightened market interest in this vision correction specialist.

The company, which specializes in implantable lenses for vision correction and maintains a healthy gross profit margin of 72%, stated that Broadwood has misrepresented introductory emails from various parties as acquisition offers. STAAR clarified that communications from three entities, referred to as Party A, Party B, and Party C, were merely introductory emails that contained no information about valuation, timing, transaction structure, or other terms necessary for a formal proposal. InvestingPro subscribers can access 8 additional key insights about STAAR’s financial health and market position through the comprehensive Pro Research Report.

According to STAAR, despite Broadwood’s assertions, the company has not received any acquisition proposals other than from Alcon during the 45-day window shop period. STAAR emphasized that Alcon’s offer represents a 59% premium to STAAR’s 90-day Volume Weighted Average Price as of August 4, 2025. With current trading volumes averaging 1.63 million shares daily and the stock trading near its Fair Value based on InvestingPro analysis, investors should closely monitor these developments.

The company urged stockholders not to be misled by Broadwood’s statements and to vote in favor of the Alcon merger at the upcoming Special Meeting scheduled for October 23. STAAR’s Board of Directors has unanimously approved the merger with Alcon.

STAAR warned that if the Alcon transaction is not approved, "the value of your shares is at risk of declining substantially," according to the statement.

The company noted that stockholders of record as of September 12, 2025, are entitled to vote at the meeting, and those with questions about voting should contact STAAR’s proxy solicitor, Innisfree M&A Incorporated.

This article is based on a press release statement issued by STAAR Surgical Company.

In other recent news, STAAR Surgical Company is urging its shareholders to vote in favor of a proposed merger with Alcon, highlighting a 59% premium to its 90-day volume-weighted average price before the announcement. The board of directors unanimously recommends the merger, which offers $28 per share in an all-cash deal, representing a significant premium to STAAR’s previous closing price and median analyst price target. Despite the 45-day "window shop" period allowing for competing bids, no alternative proposals emerged, even with active exploration by Broadwood Partners, a major stockholder opposing the merger.

Meanwhile, Yunqi Capital, a 5.1% shareholder, publicly opposed the merger, arguing that the deal undervalues STAAR and criticizing the board’s sales process. Analyst firms have also reacted to the acquisition news, with Stifel downgrading STAAR’s stock from Buy to Hold while increasing its price target to $28. Sidoti similarly downgraded the stock from Buy to Neutral, aligning its price target with the offered takeover price. The acquisition agreement values STAAR Surgical at $1.5 billion in cash.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.